Dr. Peter Martin on Alternatives to Aggressive Therapy in Mantle Cell Lymphoma

Stuart J. Schnitt, MD, discussed how AI enhances cancer diagnoses and the need for professional oversight, ethical clarity, and equitable adoption.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Colin P.N. Dinney, MD, PhD, discussed updated analyses of the BOND-003 and CORE-001 trials in bladder cancer.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.

During a live event, Krish Patel, MD, surveyed participants on using bispecific T-cell engagers vs loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.